Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Relative bioavailability of four controlled‐release nifedipine products
Biopharmaceutics & Drug Disposition, Volume 15, No. 6, Year 1994
Notification
URL copied to clipboard!
Description
Four controlled‐release nifedipine products were investigated in two clinical studies. In study 1, 22 healthy male volunteers took part in an open, multiple‐dose, randomized, crossover study to determine the relative bioavailablity of two 10 mg controlled‐release nifedipine tablet (Adalat® Retard, Bayer), administered 12 hourly, and one 20 mg controlled‐release nifedipine tablet (Adalat® Retard, Bayer) administered 12 hourly. In study 2, 24 healthy male volunteers took part in an open, multiple‐dose, randomized, three‐period, crossover study to determine the relative bioavailability of (i) two 30 mg nifedipine gastro‐intestinal therapeutic system (GITS) tablets (Adalat® XL, Bayer) administered once daily; (ii) one 60 mg nifedipine GITS tablet (Adalat® XL, Bayer) administered once daily; and (iii) one 20 mg plus one 10 mg nifedipine controlled‐release tablet (Adalat® Retard, Bayer), administered 12 hourly. In both studies detailed pharmacokinetic data, in particular with respect to the controlled‐release characteristics of the different formulations, were collected. Results of both studies indicate that all nifedipine products investigated are bioequivalent with respect to the extent of absorption of nifedipine. The nifedipine GITS products (Adalat® XL) have better controlled‐release properties than the Adalat® Retard product, and are suitable for once‐a‐day administration. Copyright © 1994 John Wiley & Sons, Ltd.
Authors & Co-Authors
Schall, Robert
South Africa, Bloemfontein
University of the Free State
Müller, Frank Otto
South Africa, Bloemfontein
University of the Free State
Hundt, Hans Karl Ludwig
South Africa, Bloemfontein
University of the Free State
Duursema, L.
South Africa, Bloemfontein
University of the Free State
Groenewoud, Gerhard
South Africa, Bloemfontein
University of the Free State
van Dyk, M.
South Africa, Bloemfontein
University of the Free State
van Schalkwyk, A. M.C.
South Africa, Bloemfontein
University of the Free State
Statistics
Citations: 8
Authors: 7
Affiliations: 1
Identifiers
Doi:
10.1002/bdd.2510150607
ISSN:
01422782
e-ISSN:
1099081X
Participants Gender
Male